Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 16, 2018

Study Completion Date

September 7, 2018

Conditions
Lymphoma, Extranodal NK-T-CellEBV
Interventions
BIOLOGICAL

baltaleucel-T

Autologous EBV-specific T-cells

Trial Locations (11)

43210

The Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic, Rochester

69310

Centre Hospitalier de Lyon, Pierre-Bénite

75015

Universitaire Ouest, Paris

77030

Baylor College of Medicine, Houston

MD Anderson Cancer Center, Houston

02215

Dana-Farber Cancer Center, Boston

135-710

Samsung Medical Center, Seoul

138-736

Asan Cancer Center, Seoul

NW1 2PG

University College London Hospital, London

M20 4BX

The Christie Clinic, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cell Medica Ltd

INDUSTRY

NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma | Biotech Hunter | Biotech Hunter